Welcome to Madrigal Pharmaceuticals Fourth Quarter 2024 Earnings Conference Call. (Operator Instructions) As a reminder, today's conference call is being recorded. I'd like to introduce Ms. Tina ...

Moving to Slide 10 and the unmet need in compensated MASH cirrhosis. It's a chronic progressive liver disease characterized by significant liver damage, loss of liver function, liver cancer and death.

Q4 2024 Earnings Call Transcript March 6, 2025 Atea Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is ...

Company announcement - No. 2 / 2025 Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant clinical advancement across differentiated obesity pipeli ...

You can access the press release as well as the slides that we'll be reviewing today ... And let's not forget that in the United States, 70% of liver cancer is a consequence of HCV disease ...

No. 2 / 2025Correction includes 2024 Annual Report attached in iXBRL format. Zealand Pharma Announces Financial Results for the Full Year 2024A transformational year with significant clinical ...

Discover the 5 ways alcohol progressively harms your liver, from early warning signs to serious complications, plus expert ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

Liver cirrhosis is a progressive disease that affects millions worldwide, leading to severe complications such as hepatic ...

At 2 years, participants in the compensated MASH cirrhosis treatment arm of the MAESTRO-NAFLD-1 trial experienced a ...